EN Official Journal of the European Union C 44/6

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2011

2012/C 44/05

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January-30 June 2011, at their meeting on 30 September 2011:

Annex I List of new marketing authorisations Annex II List of renewed marketing authorisations Annex III List of extended marketing authorisations Annex IV List of withdrawn marketing authorisations Annex V List of suspended marketing authorisations

ANNEX I List of new marketing authorisations The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January-30 June 2011: EU-Number Product Country Date of authorisation EU/1/09/578/001 Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals Iceland 29.4.2011 EU/1/10/635/001-014 Olanzapin Apotex Norway 14.2.2011 EU/1/10/639/001-030 Telmisartan Actavis Norway 17.3.2011 EU/1/10/641/001 Ruconest Iceland 24.1.2011 EU/1/10/642/001-004 Ibandronic Acid Teva Iceland 17.1.2011 EU/1/10/647/001-002 Myclausen Iceland 21.1.2011 EU/1/10/647/001-028 Twynsta Iceland 21.1.2011 EU/1/10/650/001-015 Clopidogrel Teva Generics BV Iceland 1.2.2011 EU/1/10/651/001-015 Clopidogrel HCS Iceland 1.2.2011 EU/1/10/654/001-004 Leflunomide ratiopharm Iceland 14.3.2011 EU/1/10/656/001-006 Possia Iceland 13.1.2011 EU/1/10/656/001-006 Possia Norway 25.1.2011 EU/1/10/657/001-002 Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Dia Iceland 14.3.2011 EU/1/10/657/001-002 Prepandemic Influenza Vaccine Norway 3.1.2011 EU/1/10/658/001-002 Aflunov Iceland 14.3.2011 EU/1/10/658/001-002 Aflunov Norway 3.1.2011 EU/1/10/659/001-010 Iasibon Iceland 14.2.2011 EU/1/10/659/001-010 Iasibon Norway 17.2.2011 EU/1/10/659/001-010 Iasibon Liechtenstein 28.2.2011 EU/1/10/660/001-002 Potactasol Iceland 16.3.2011 EU/1/10/660/001-002 Potactasol Liechtenstein 28.2.2011 EU/1/10/661/001-002 Fluenz Iceland 16.3.2011 EU/1/10/661/001-002 Fluenz Liechtenstein 28.2.2011 EU/1/10/662/001-002 Docetaxel Teva Pharma Iceland 17.2.2011 EU/1/10/662/001-002 Docetaxel Teva Pharma Liechtenstein 28.2.2011 EU/1/10/662/001-002 Docetaxel Teva Pharma Norway 17.3.2011 EU/1/10/662/001-002 Docetaxel Teva Pharma Norway 17.3.2011 EU/1/10/663/001-002 Lamivudine/Zidovudine Teva Norway 31.3.2011 EU/1/10/663/001-002 Lamivudine/Zidovudine Teva Liechtenstein 30.4.2011 EU/1/10/664/001 Pumarix Iceland 8.4.2011 EU/1/10/664/001 Pumarix Norway 13.4.2011 EU/1/10/664/001 Pumarix Liechtenstein 30.4.2011 EU/1/10/665/001-004 Entacapone Teva Iceland 21.3.2011 EU/1/10/665/001-004 Entacapone Teva Norway 4.4.2011 EU/1/10/665/001-004 Entacapone Teva Liechtenstein 30.4.2011 EU/1/11/666/001-003 Libertek Iceland 24.3.2011 EU/1/11/666/001-003 Libertek Norway 15.3.2011 EU/1/11/666/001-003 Libertek Liechtenstein 30.4.2011 EU/1/11/667/001-003 Esbriet Liechtenstein 30.4.2011 EU/1/11/667/001-003 Esbriet Iceland 25.3.2011 EU/1/11/667/001-003 Esbriet Norway 15.3.2011 EU/1/11/667/001-003 Esbriet Norway 15.3.2011 EU/1/11/668/001-003 Daliresp Iceland 12.4.2011 EU/1/11/668/001-003 Daliresp Norway 15.3.2011 EU/1/11/668/001-003 Daliresp Liechtenstein 30.4.2011 EU/1/11/669/001-004 Teysuno Iceland 12.4.2011 EU/1/11/669/001-004 Teysuno Norway 24.5.2011 EU/1/11/669/001-004 Teysuno Liechtenstein 30.4.2011 EU/1/11/671/001 Xiapex Iceland 28.3.2011 EU/1/11/671/001 Xiapex Norway 31.3.2011 EU/1/11/671/001 Xiapex Liechtenstein 30.4.2011 EU/1/11/672/001-006 Xeplion Iceland 8.4.2011 EU/1/11/672/001-006 Xeplion Norway 5.4.2011 EU/1/11/672/001-006 Xeplion Liechtenstein 30.4.2011 EU/1/11/673/001-024 Ifirmacombi Iceland 4.4.2011 EU/1/11/673/001-024 Ifirmacombi Norway 6.4.2011 EU/1/11/673/001-024 Ifirmacombi Liechtenstein 30.4.2011 EU/1/11/674/001-010 Repso Iceland 13.4.2011 EU/1/11/674/001-010 Repso Norway 26.4.2011 EU/1/11/674/001-010 Repso Liechtenstein 30.4.2011 EU/1/11/675/001-0010 Leflunomide Teva Iceland 8.4.2011 EU/1/11/675/001-010 Lefluomide Teva Norway 11.4.2011 EU/1/11/675/001-010 Leflunomid Teva Liechtenstein 30.4.2011 EU/1/11/676/001 Jevtana Iceland 12.4.2011 EU/1/11/676/001 Jevtana Norway 6.4.2011 EU/1/11/676/001 Jevtana Liechtenstein 30.4.2011 EU/1/11/677/001-004 Gilenya Iceland 13.4.2011 EU/1/11/677/001-004 Gilenya Norway 28.3.2011 EU/1/11/677/001-004 Gilenya Liechtenstein 30.4.2011 EU/1/11/678/001-002 Halaven Iceland 14.4.2011 EU/1/11/678/001-002 Halaven Norway 6.4.2011 EU/1/11/678/001-002 Halaven Liechtenstein 30.4.2011 EU/1/11/679/001-006 Pravafenix Iceland 10.5.2011 EU/1/11/679/001-006 Pravafenix Norway 11.5.2011 EU/1/11/679/001-006 Pravafenix Liechtenstein 30.4.2011 EU/1/11/680/001-080 Riprazo HCT Iceland 29.4.2011 EU/1/11/680/001-080 Riprazo HCT Norway 24.5.2011 EU/1/11/680/001-080 Riprazo HCT Liechtenstein 30.4.2011 EU/1/11/681/001-013 Trobalt Iceland 19.4.2011 EU/1/11/681/001-013 Trobalt Norway 4.4.2011 EU/1/11/681/001-013 Trobalt Liechtenstein 30.6.2011 EU/1/11/681/001-013 Trobalt Liechtenstein 30.4.2011 EU/1/11/682/001 Methylthioninium chloride Proveblue Iceland 6.6.2011 EU/1/11/682/001 Methylhionininium chloride Proveblue Norway 27.6.2011 EU/1/11/682/001 Methylthioninchlorid Proveblue Liechtenstein 30.6.2011 EU/1/11/686/001-056 Rasilamlo Iceland 12.5.2011 EU/1/11/686/001-056 Rasilamlo Norway 24.5.2011 EU/1/11/686/001-056 Rasilamlo Liechtenstein 30.4.2011 EU/1/11/687/001-012 Hizentra Iceland 12.5.2011 EU/1/11/687/001-012 Hizentra Norway 9.5.2011 EU/1/11/687/001-012 Hizentra Liechtenstein 30.4.2011 EU/1/11/688/001 Cinryze Iceland 28.6.2011 EU/1/11/688/001 Cinryze Norway 27.6.2011 EU/1/11/691/001-005 Eliquis Norway 31.5.2011 EU/1/11/691/001-005 Eliquis Liechtenstein 30.6.2011 EU/1/11/692/001 Yellox Iceland 28.6.2011 EU/1/11/692/001 Yellox Norway 10.6.2011 EU/1/11/692/001 Yellox Liechtenstein 30.6.2011 EU/1/11/693/001-016 Rivastigmine Actavis Iceland 28.6.2011 EU/1/11/693/001-016 Rivastigmine Actavis Liechtenstein 30.6.2011 EU/1/190/649/001-016 Clopidogrel Teva Pharma BV Iceland 30.6.2011 EU/1/98/058/001-002 Lamivudine/Zidovudine Teva Iceland 12.4.2011 EU/1/98/058/001-002 Lamivudine Norway 31.3.2011 EU/2/11/120/001-003 Zulvac 1 + 8 Ovis Liechtenstein 30.4.2011 EU/2/11/126/001 MS-H Impfstoff Liechtenstein 30.6.2011 EU/2/10/107/001-014 Veraflox Iceland 10.5.2011 EU/2/10/107/001-014 Veraflox Norway 24.6.2011 EU/2/10/107/001-014 Veraflox Liechtenstein 30.4.2011 EU/2/10/109/001-009 RHINISENG Norway 3.1.2011 EU/2/10/110/001-002 Coxevac Iceland 26.1.2011 EU/2/10/111/001-004 Meloxoral Iceland 14.3.2011 EU/2/10/111/001-004 Meloxoral Norway 3.1.2011 EU/2/10/112/001-005 BTVPUR ALSap 1 Iceland 10.2.2011 EU/2/10/112/001-005 BTVPUR ALSap 1 Liechtenstein 28.2.2011 EU/2/10/113/001-005 BTVPUR ALSap 1-8 Iceland 10.2.2011 EU/2/10/113/001-005 BTVPUR ALSap 1-8 Liechtenstein 28.2.2011 EU/2/10/114/001-002 Hiprabovis IBR Marker Live Iceland 16.3.2011 EU/2/10/114/001-002 Hiprabovis IBR Marker Live Norway 9.2.2011 EU/2/10/114/001-002 Hiprabovis IBR Marker Live Liechtenstein 28.2.2011 EU/2/10/115/001-010 Comfortis Iceland 22.3.2011 EU/2/10/115/001-010 Comfortis Norway 22.2.2011 EU/2/10/115/001-010 Comfortis Liechtenstein 30.4.2011 EU/2/10/115/001-010 Comfortis Norway 22.2.2011 EU/2/10/116/001-004 Melosus Iceland 24.3.2011 EU/2/10/116/001-004 Melosus Norway 14.4.2011 EU/2/10/116/001-004 Melosus Liechtenstein 30.4.2011 EU/2/10/117/001-002 Purevax Rabies Iceland 21.3.2011 EU/2/10/117/001-002 Purevax Rabies Norway 4.4.2011 EU/2/10/117/001-002 Purevax Rabies Liechtenstein 30.4.2011 EU/2/10/118/001-014 Activyl Iceland 21.3.2011 EU/2/10/118/001-014 Activyl Norway 1.4.2011 EU/2/10/118/001-014 Activyl Liechtenstein 30.4.2011 EU/2/10/119/001-012 Cimalgex Iceland 21.3.2011 EU/2/10/119/001-012 Cimalgex Norway 1.4.2011 EU/2/108/001-005 BTVPUR ALSap 2-4 0.72 U.SN Iceland 10.2.2011 EU/2/11/120/001-003 Zulvac 1 + 8 Ovis Iceland 13.4.2011 EU/2/11/120/001-003 Zulvac 1 + 8 Ovis Norway 18.4.2011 EU/2/11/121/001-009 CaniLeish Iceland 13.4.2011 EU/2/11/121/001-009 CaniLeish Norway 11.4.2011 EU/2/11/121/001-009 CaniLeish Liechtenstein 30.4.2011 EU/2/11/123/001-002 Procox Iceland 28.6.2011 EU/2/11/123/001-002 Procox Norway 20.6.2011 EU/2/11/123/001-002 Procox Liechtenstein 30.6.2011 EU/2/11/124/001-008 Zuprevo Iceland 6.6.2011 EU/2/11/124/001-008 Zuprevo Liechtenstein 30.6.2011 EU/2/11/125/001-008 Certifect Iceland 6.6.2011 EU/2/11/125/001-008 Certificet Liechtenstein 30.6.2011 EU/2/11/126/001 MS-H-vaccine Iceland 28.6.2011

ANNEX II List of renewed marketing authorisations The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January-30 June 2011: EU-Number Product Country Date of authorisation EU/1/00/135/001-002 DaTSCAN Iceland 14.3.2011 EU/1/00/149/001 Panretin Iceland 18.1.2011 EU/1/00/156/002-004 Trizivir Iceland 14.2.2011 EU/1/00/166/001-003 NeuroBloc Iceland 15.2.2011 EU/1/00/166/001-003 NeuroBloc Norway 15.2.2011 EU/1/00/167/001-008 Prevenar Iceland 25.3.2011 EU/1/00/167/001-008 Prevenar Norway 3.3.2011 EU/1/00/167/001-008 Prevenar Liechtenstein 28.2.2011 EU/1/00/173/001-003 Vaniqa Iceland 15.4.2011 EU/1/01/171/001, 007-010, 013-014 Rapamune Iceland 21.2.2011 EU/1/01/171/001, EU/1/01/171/007-010 EU/1/01/171/013-014 Rapamune Norway 2.2.2011 EU/1/01/172/001-008 Kaletra Iceland 21.3.2011 EU/1/01/172/001-008 Kaletra Norway 27.4.2011 EU/1/01/172/001-008 Kaletra Liechtenstein 30.4.2011 EU/1/01/173/001-003 Vaniqa Norway 3.5.2011 EU/1/01/173/001-003 Vaniqa Liechtenstein 30.4.2011 EU/1/01/179/001 Osigraft Iceland 17.5.2011 EU/1/01/179/001 Osigraft Norway 15.6.2011 EU/1/01/179/001 Osigraft Liechtenstein 30.6.2011 EU/1/01/183/001&004-005, 007-008, 011, 013, 015, 018-032 HBVAXPRO Iceland 18.4.2011 EU/1/01/183/001, EU/1/01/183/004-005 EU/1/01/183/007-008, EU/1/01/183/011 EU/1/01/183/013, EU/1/01/183/015 EU/1/01/183/018-032 HBVAXPRO Norway 14.4.2011 EU/1/01/187/001 DepoCyte Iceland 23.6.2011 EU/1/01/187/001 DepoCyte Liechtenstein 30.6.2011 EU/1/01/191/001-005 Ketek 400 mg Iceland 9.6.2011 EU/1/01/191/001-005 Ketek Norway 31.5.2011 EU/1/01/191/001-005 Ketek Liechtenstein 30.6.2011 EU/1/01/193/001-002 MabCampath Iceland 23.6.2011 EU/1/01/193/001-002 MabCampath Norway 15.6.2011 EU/1/05/312/001 Xyrem Iceland 14.1.2011 EU/1/05/313/001-009 Ablavar Iceland 28.1.2011 EU/1/05/314/001 Kepivance Iceland 17.1.2011 EU/1/05/315/001-002 Aptivus Iceland 27.1.2011 EU/1/05/320/001 Noxafil Iceland 18.1.2011 EU/1/05/322/001 Yttriga Iceland 18.3.2011 EU/1/05/322/001 Yttriga Norway 20.1.2011 EU/1/05/322/001 Yttriga Liechtenstein 28.2.2011 EU/1/05/323/001-013 ProQuad Iceland 15.4.2011 EU/1/05/323/001-013 ProQuad Norway 6.4.2011 EU/1/05/323/001-013 ProQuad Liechtenstein 30.4.2011 EU/1/05/324/001-002 Naglazyme Iceland 23.3.2011 EU/1/05/324/001-002 Naglazyme Norway 7.2.2011 EU/1/05/324/001-002 Naglazyme Liechtenstein 28.2.2011 EU/1/05/325/002 Macugen Iceland 15.2.2011 EU/1/05/325/002 Macugen Norway 1.2.2011 EU/1/05/325/002 Macugen Liechtenstein 28.2.2011 EU/1/05/328/001-004 Cubicin Iceland 14.2.2011 EU/1/05/328/001-004 Cubicin Norway 11.1.2011 EU/1/05/329/001-006 Kiovig Iceland 24.2.2011 EU/1/05/329/001-006 Kiovig Norway 2.2.2011 EU/1/05/329/001-006 Kiovig Liechtenstein 28.2.2011 EU/1/05/330/001-011 Rotarix Iceland 22.3.2011 EU/1/05/330/001-011 Rotarix Norway 13.5.2011 EU/1/05/331/001-055 Neupro Iceland 15.2.2011 EU/1/05/331/001-055 Neupro Norway 10.1.2011 EU/1/06/332/001-009 Omnitrope Iceland 28.6.2011 EU/1/06/332/001-009 Omnitrope Norway 5.4.2011 EU/1/06/332/001-009 Omnitrope Liechtenstein 30.4.2011 EU/1/06/333/001-003 Myozyme Iceland 20.4.2011 EU/1/06/333/001-003 Myozyme Norway 22.3.2011 EU/1/06/333/001-003 Myozyme Liechtenstein 30.4.2011 EU/1/06/334/001-005 Evoltra Iceland 18.4.2011 EU/1/06/334/001-005 Evoltra Norway 25.5.2011 EU/1/06/334/001-005 Evoltra Liechtenstein 30.4.2011 EU/1/06/335/001 Valtropin Iceland 12.5.2011 EU/1/06/335/001 Valtropin Norway 3.6.2011 EU/1/06/335/001 Valtropin Liechtenstein 30.4.2011 EU/1/06/336/001 Tygacil Norway 31.5.2011 EU/1/06/336/001 Tygacil Liechtenstein 30.6.2011 EU/1/06/337/001-013 M-M-RVAXPRO Iceland 16.5.2011 EU/1/06/337/001-013 M-M-RVAXPRO Norway 31.5.2011 EU/1/06/337/001-013 M-M-RVAXPRO Liechtenstein 30.6.2011 EU/1/06/338/001-003 DuoTrav Iceland 21.1.2011 EU/1/06/339/001-002 Preotact Iceland 11.5.2011 EU/1/06/339/001-002 Preotact Liechtenstein 30.4.2011 EU/1/06/341/001-013 Zostavax Iceland 18.4.2011 EU/1/06/341/001-013 Zostavax Liechtenstein 30.4.2011 EU/1/06/343/001-007 Baraclude Iceland 23.6.2011 EU/1/06/343/001-007 Baraclude Liechtenstein 30.6.2011 EU/1/06/346/001 Tysabri Iceland 27.6.2011 EU/1/06/348/001-002 RotaTeq Iceland 23.6.2011 EU/1/06/348/001-002 RotaTeq Norway 17.6.2011 EU/1/06/348/001-002 RotaTeq Liechtenstein 28.2.2011 EU/1/06/354/001-011 Competact Iceland 24.6.2011 EU/1/06/354/001-011 Competact Norway 23.6.2011 EU/1/06/354/001-011 Competact Liechtenstein 30.6.2011 EU/1/06/360/001-013 Champix Liechtenstein 30.6.2011 EU/1/06/367/001-012 Diacomit Iceland 11.2.2011 EU/1/06/367/001-012 Diacomit Norway 15.2.2011 EU/1/06/367/001-012 Diacomit Liechtenstein 28.2.2011 EU/1/07/423/001-003 Vectibix Iceland 15.2.2011 EU/1/07/423/001-003 Vectibix Norway 25.1.2011 EU/1/07/440/001-003 Tyverb Norway 3.6.2011 EU/1/10/625/001 Arzerra Iceland 22.2.2011 EU/1/10/625/001-002 Arzerra Norway 17.2.2011 EU/1/10/625/001-002 Arzerra Liechtenstein 28.2.2011 EU/1/10/628/001-004 Votrient Iceland 6.6.2011 EU/1/183/001, 004-005, 007-008, 011, 013, 015, 018-032 HBVAXPRO Liechtenstein 30.4.2011 EU/1/96/009/001-008 Zerit Iceland 16.5.2011 EU/1/96/009/001-009 Zerit Norway 6.5.2011 EU/1/96/009/001-009 Zerit Liechtenstein 30.4.2011 EU/2/00/026/001-004 Porcilis AR-T DF Norway 3.1.2011 EU/2/00/026/001-006 Porcilis AR-T DF Iceland 17.1.2011 EU/2/04/045/001-007 Previcox Norway 18.4.2011 EU/2/04/048/001-002 Purevax RCP FeLV Norway 13.4.2011 EU/2/04/049/001-002 Purevax RCCh Norway 13.4.2011 EU/2/04/050/001-002 Purevax RCPCh Norway 13.4.2011 EU/2/04/051/001-002 Purevax RC Norway 13.4.2011 EU/2/04/052/001-002 Purevax RCP Norway 13.4.2011 EU/2/06/058/004 Flexicam Iceland 8.4.2011 EU/2/06/058/004 Flexicam Norway 26.4.2011 EU/2/06/058/004 Flexicam Liechtenstein 30.4.2011 EU/2/06/059/001 Convenia Iceland 27.6.2011

ANNEX III List of extended marketing authorisations The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January-30 June 2011: EU-Number Product Country Date of authorisation EU/1/01/185/100-111 Aranesp Iceland 15.4.2011 EU/1/01/194/003-004 INOmax Iceland 15.4.2011 EU/1/02/227/003 Neulasta Liechtenstein 30.4.2011 EU/1/06/332/010-012 Omnitrope Iceland 16.6.2011 EU/1/06/332/010-012 Omnitrope Liechtenstein 30.6.2011 EU/1/06/354/010-011 Competact Liechtenstein 28.2.2011 EU/1/06/354/012 Competact Liechtenstein 30.6.2011 EU/1/06/370/037-039 Exforge Liechtenstein 28.2.2011 EU/1/06/371/037-039 Dafiro Liechtenstein 28.2.2011 EU/1/06/373/037-039 Imprida Liechtenstein 28.2.2011 EU/1/07/387/014-026 Advagraf Liechtenstein 30.6.2011 EU/1/07/397/002-004 Siklos Iceland 25.3.2011 EU/1/07/397/002-004 Siklos Norway 5.4.2011 EU/1/07/397/002-004 Siklos Liechtenstein 30.4.2011 EU/1/07/401/012-015 Alli Iceland 16.2.2011 EU/1/07/401/012-015 Alli Norway 26.1.2011 EU/1/07/404/006-008 Flebogamma DIF Iceland 17.2.2011 EU/1/07/404/006-008 Flebogamma DIF Norway 14.1.2011 EU/1/07/404/006-008 Flebogamma DIF Liechtenstein 28.2.2011 EU/1/07/407/021-040 Sprimeo Liechtenstein 30.4.2011 EU/1/07/410/027-052 Binocrit Liechtenstein 30.4.2011 EU/1/07/411/027-052 Epoetin alfa Hexal Liechtenstein 30.4.2011 EU/1/07/420/002 Cyanokit Iceland 20.1.2011 EU/1/07/420/002 Cyanokit Norway 14.2.2011 EU/1/07/422/005-006 Tasigna Iceland 23.3.2011 EU/1/07/422/005-006 Tasigna Norway 21.1.2011 EU/1/07/422/005-006 Tasigna Liechtenstein 28.2.2011 EU/1/07/438/005-006 Myfenax Liechtenstein 30.6.2011 EU/1/07/439/005-006 Mycophenole mofetil Teva Liechtenstein 30.6.2011 EU/1/08/461/002 Firazyr Liechtenstein 30.4.2011 EU/1/08/490/017-024 Pramipexole Teva Liechtenstein 30.6.2011 EU/1/09/511/005 Conbriza Liechtenstein 30.4.2011 EU/1/09/535/015-016 Grepid Liechtenstein 28.2.2011 EU/1/09/545/011-015 Onglyza Iceland 14.4.2011 EU/1/09/545/011-015 Onglyza Norway 25.3.2011 EU/1/09/545/011-015 Onglyza Liechtenstein 30.4.2011 EU/1/09/581/003-008 Resolor Liechtenstein 28.2.2011 EU/1/10/614/002 Menveo Liechtenstein 30.4.2011 EU/1/96/022/035-040 Zyprexa Liechtenstein 28.2.2011 EU/1/97/033/005-006 Avonex Liechtenstein 30.6.2011 EU/1/99/103/005 ReFacto AF Iceland 6.6.2011 EU/1/99/103/005-008 ReFacto AF Norway 1.6.2011 EU/1/99/103/005-008 ReFacto AF Liechtenstein 30.6.2011 EU/2/07/078/009-010 Rheumocam Iceland 18.4.2011 EU/2/07/078/009-010 Rheumocam Norway 9.2.2011 EU/2/07/078/009-010 Rheumocam Liechtenstein 28.2.2011 EU/2/07/078/011-014 Rheumocam Iceland 28.6.2011 EU/2/07/078/011-014 Rheumocam Liechtenstein 30.6.2011 EU/2/08/082/007 Zactran Liechtenstein 30.6.2011 EU/2/97/004/041-048 Metacam Liechtenstein 28.2.2011 EU/2/98/010/025 Econor Iceland 18.2.2011 EU/2/98/010/025 Econor Liechtenstein 28.2.2011 EU/99/119/017-018 NovoRapid Liechtenstein 30.4.2011

ANNEX IV List of withdrawn marketing authorisations The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January-30 June 2011: EU-Number Product Country Date of withdrawal EU/1/03/259/001-006 Onsenal Iceland 20.4.2011 EU/1/03/259/001-006 Onsenal Liechtenstein 30.4.2011 EU/1/05/326/001 Ionsys Iceland 20.4.2011 EU/1/06/353/001-005 Thelin Iceland 15.3.2011 EU/1/06/353/001-005 Thelin Liechtenstein 28.2.2011 EU/1/08/449/001-008 Filgrastim ratiopharm Liechtenstein 30.4.2011 EU/1/08/449/001-008 Filgrastim ratiopharm Iceland 12.5.2011 EU/1/09/542/001-007 Clopidogrel 1A Pharma Liechtenstein 28.2.2011 EU/1/09/542/001-007 Clopidogrel 1A Pharma Iceland 16.3.2011 EU/1/09/547/001-007 Clopidogrel Sandoz Liechtenstein 30.4.2011 EU/1/10/629/001 Humenza Iceland 29.6.2011 EU/1/10/629/001 Humenza Liechtenstein 30.6.2011